• BridgeBio flagged new clinical and real-world data for acoramidis in ATTR-CM scheduled for HFSA ASM 2026 on Oct. 9-12.
• Presentations will highlight evidence supporting acoramidis as a first-line option, including reduced death risk and fewer cardiovascular hospitalizations.
• Additional readouts will address functional capacity, quality of life, kidney-related signals post-initiation, and comparative effectiveness versus tafamidis using EHR data.
• Acoramidis is marketed as Attruby in the U.S. and BEYONTTRA in multiple ex-U.S. markets, positioning the program for broader commercial uptake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061601PRIMZONEFULLFEED9840079) on October 06, 2026, and is solely responsible for the information contained therein.